Salud financiera de hoja de balance de OncoSec Medical

Salud financiera controles de criterios 0/6

OncoSec Medical tiene un patrimonio de los accionistas total de $-5.5M y una deuda total de $7.3M, lo que sitúa su ratio deuda-patrimonio en -132.9%. Sus activos y pasivos totales son $8.9M y $14.4M respectivamente.

Información clave

-132.9%

Ratio deuda-patrimonio

US$7.29m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$3.68m
Patrimonio	-US$5.49m
Total pasivo	US$14.36m
Activos totales	US$8.87m

Actualizaciones recientes sobre salud financiera

Recent updates

OncoSec to cut workforce by 45% as part of corporate restructuring

Oct 04

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

Jan 28

Dosing underway in OncoSec's Tavo combo trial in skin cancer

Jan 08

OncoSec: Undervalued And Continuing To Make Progress

Nov 18

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

Nov 09

Análisis de la situación financiera

Pasivos a corto plazo: ONCS.Q tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: ONCS.Q tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: ONCS.Q tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: ONCS.Q tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ONCS.Q tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ONCS.Q tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 11.8% cada año

Salud financiera de hoja de balance de OncoSec Medical

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Price target decreased to US$5.00

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

Price target decreased to US$5.00

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

Price target raised to US$8.13

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: US$7.71

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: US$6.81

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Dosing underway in OncoSec's Tavo combo trial in skin cancer

New 90-day high: US$6.65

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec: Undervalued And Continuing To Make Progress

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

New 90-day high: US$5.11

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera